HIGHLIGHTS
- who: Giselle L. Saulnier Sholler and collaborators from the Institute, UNITED Medicine, Michigan State University, Grand Rapids, Michigan, United, Cancer have published the paper: A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma, in the Journal: PLOS ONE | DOI:10.1371/journal.pone [0127246]. May 27, 2015 of May/27,/2015
- what: This study investigated safety response pharmacokinetics genetic and metabolic factors associated with ODC in clinical trial the ODC inhibitor difluoromethylornithine (DFMO) ± etoposide for patients with relapsed or NB. To address the safety issue, patient replacement was allowed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.